Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Angiogenesis
Apatinib
Metastasis
Ovarian Cancer
PD-L1
VEGFR2
Zebrafish
c-JUN
Journal
Cancer communications (London, England)
ISSN: 2523-3548
Titre abrégé: Cancer Commun (Lond)
Pays: United States
ID NLM: 101723675
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
27
11
2020
received:
12
08
2020
accepted:
23
03
2021
pubmed:
4
5
2021
medline:
25
2
2023
entrez:
3
5
2021
Statut:
ppublish
Résumé
Although programmed cell death-ligand 1 (PD-L1) plays a well-known function in immune checkpoint response by interacting with programmed cell death-1 (PD-1), the cell-intrinsic role of PD-L1 in tumors is still unclear. Here, we explored the molecular regulatory mechanism of PD-L1 in the progression and metastasis of ovarian cancer. Immunohistochemistry of benign tissues and ovarian cancer samples was performed, followed by migration, invasion, and angiogenesis assays in PD-L1-knockdown ovarian cancer cells. Immunoprecipitation, mass spectrometry, and chromatin immunoprecipitation were conducted along with zebrafish and mouse experiments to explore the specific functions and mechanisms of PD-L1 in ovarian cancer. Our results showed that PD-L1 induced angiogenesis, which further promoted cell migration and invasion in vitro and in vivo of ovarian cancer. Mechanistically, PD-L1 was identified to directly interact with vascular endothelial growth factor receptor-2 (VEGFR2) and then activated the FAK/AKT pathway, which further induced angiogenesis and tumor progression, leading to poor prognosis of ovarian cancer patients. Meanwhile, PD-L1 was found to be regulated by the oncogenic transcription factor c-JUN at the transcriptional level, which enhanced the expression of PD-L1 in ovarian cancer. Furthermore, we demonstrated that PD-L1 inhibitor durvalumab, combined with the antiangiogenic drug, apatinib, could enhance the effect of anti-angiogenesis and the inhibition of cell migration and invasion. Our results demonstrated that PD-L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c-JUN/VEGFR2 signaling axis, suggesting that the combination of PD-L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients.
Sections du résumé
BACKGROUND
Although programmed cell death-ligand 1 (PD-L1) plays a well-known function in immune checkpoint response by interacting with programmed cell death-1 (PD-1), the cell-intrinsic role of PD-L1 in tumors is still unclear. Here, we explored the molecular regulatory mechanism of PD-L1 in the progression and metastasis of ovarian cancer.
METHODS
Immunohistochemistry of benign tissues and ovarian cancer samples was performed, followed by migration, invasion, and angiogenesis assays in PD-L1-knockdown ovarian cancer cells. Immunoprecipitation, mass spectrometry, and chromatin immunoprecipitation were conducted along with zebrafish and mouse experiments to explore the specific functions and mechanisms of PD-L1 in ovarian cancer.
RESULTS
Our results showed that PD-L1 induced angiogenesis, which further promoted cell migration and invasion in vitro and in vivo of ovarian cancer. Mechanistically, PD-L1 was identified to directly interact with vascular endothelial growth factor receptor-2 (VEGFR2) and then activated the FAK/AKT pathway, which further induced angiogenesis and tumor progression, leading to poor prognosis of ovarian cancer patients. Meanwhile, PD-L1 was found to be regulated by the oncogenic transcription factor c-JUN at the transcriptional level, which enhanced the expression of PD-L1 in ovarian cancer. Furthermore, we demonstrated that PD-L1 inhibitor durvalumab, combined with the antiangiogenic drug, apatinib, could enhance the effect of anti-angiogenesis and the inhibition of cell migration and invasion.
CONCLUSION
Our results demonstrated that PD-L1 promoted the angiogenesis and metastasis of ovarian cancer by participating in the c-JUN/VEGFR2 signaling axis, suggesting that the combination of PD-L1 inhibitor and antiangiogenic drugs may be considered as a potential therapeutic approach for ovarian cancer patients.
Identifiants
pubmed: 33939321
doi: 10.1002/cac2.12157
pmc: PMC8211352
doi:
Substances chimiques
B7-H1 Antigen
0
Vascular Endothelial Growth Factor A
0
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-527Informations de copyright
© 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.
Références
Oncogene. 2018 Jul;37(30):4164-4180
pubmed: 29706653
Cell Oncol (Dordr). 2019 Oct;42(5):679-690
pubmed: 31325096
Cancers (Basel). 2018 Mar 28;10(4):
pubmed: 29597249
Crit Rev Oncol Hematol. 2015 Oct;96(1):113-28
pubmed: 26126494
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Front Biosci (Schol Ed). 2015 Jun 01;7:226-35
pubmed: 25961698
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Int J Mol Sci. 2020 Oct 29;21(21):
pubmed: 33138288
Biosci Rep. 2019 Dec 20;39(12):
pubmed: 31799599
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Front Immunol. 2019 Apr 26;10:867
pubmed: 31105696
Transl Oncol. 2020 Feb;13(2):336-345
pubmed: 31881506
Aging (Albany NY). 2019 Dec 27;11(24):12568-12580
pubmed: 31881008
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Cancer Commun (Lond). 2020 Aug;40(8):380-385
pubmed: 32428376
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Cancer. 2020 Jul 9;11(18):5353-5358
pubmed: 32742481
Front Oncol. 2020 Apr 30;10:632
pubmed: 32426281
Cancer Med. 2020 Aug;9(16):5899-5907
pubmed: 32627959
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Br J Cancer. 2015 Apr 28;112(9):1501-9
pubmed: 25867264
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Cell Prolif. 2019 May;52(3):e12571
pubmed: 30714229
Biomed Pharmacother. 2020 Mar;123:109780
pubmed: 31901550
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Front Oncol. 2020 Aug 25;10:1451
pubmed: 32983976
J Cell Biochem. 2020 Mar;121(3):2247-2257
pubmed: 31693227
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Future Oncol. 2020 Mar;16(7):225-246
pubmed: 31746224
Int J Colorectal Dis. 2021 Jan;36(1):117-130
pubmed: 32910207
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
Pharmacol Res. 2018 Feb;128:366-375
pubmed: 28951297
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Front Cell Dev Biol. 2020 Nov 19;8:595585
pubmed: 33330483
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Med Oncol. 2015 Aug;32(8):212
pubmed: 26141060
Cancer Commun (Lond). 2021 Jun;41(6):511-527
pubmed: 33939321
Cancer Res. 2011 Feb 15;71(4):1235-43
pubmed: 21159661
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Expert Opin Biol Ther. 2018 Jun;18(6):707-717
pubmed: 29781343
Cancer Res. 2019 May 15;79(10):2604-2618
pubmed: 30808674
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259
pubmed: 30285216